Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma

Status:
Completed

Trial end date:
2009-04-01

Target enrollment:

Participant gender:

To determine the tolerability, safety, end-organ toxicity and maximum tolerated dose of AS1409 in single and repeated doses.

Phase 1

Antisoma Research